Golden Biotechnology Corporation reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was TWD 60.93 million compared to TWD 36.2 million a year ago. Net loss was TWD 207.76 million compared to TWD 219.69 million a year ago. Basic loss per share from continuing operations was TWD 1.46 compared to TWD 1.66 a year ago.